Cancer Research Institute Named Finalist for CLASSY Awards
CRI’s Clinical Accelerator recognized for innovation in advancing cancer immunotherapy
NEW YORK (Mar. 17, 2014) — The Cancer Research Institute’s Clinical Accelerator has been named a Top Nominee for the Annual CLASSY Awards in the Cancer Services Category. The CLASSYs recognize leaders in their field making monumental strides toward solving important social challenges.
The Cancer Research Institute (CRI), a New York-based nonprofit committed to developing immune system-based cancer treatments, created the Clinical Accelerator as a way to speed up development of the most promising new immunotherapies. To achieve this, the accelerator facilitates a collaboration of top scientists and companies from around the world who work together to identify, develop, and study novel treatments with transformational potential for patients, and then helps kick-start their development using a one-of-a-kind set of nonprofit financial and clinical resources.
“It’s an incredible honor to be one of the top nominees,” said Adam Kolom, the accelerator’s director. “The work coming out of the Clinical Accelerator is changing the way cancer is treated right now and it will play an increasingly important role over the next 10 years as the field works together to unlock immunotherapy’s full curative potential for cancer patients. We’re very appreciative of CLASSYs’ recognition of our work and of this new, more collaborative approach to treatment development.”
Working with Ludwig Cancer Research, CRI’s partner in the collaborative strategy, the two nonprofits have built an unrivaled network of top cancer immunotherapy experts and access to the best new drugs. Therapies developed by the Clinical Accelerator will treat more than 500 people this year, and the insights gained through this research will help guide the future development of even more powerful medicines that will set a new standard of improved care for cancer patients.
“The Clinical Accelerator is making great progress toward finding the most effective combinations of cancer immunotherapy drugs,” said Dr. Jill O’Donnell-Tormey, CEO and director of scientific affairs at CRI. “It’s exciting to see the accelerator poised to have such a near-term positive impact on the way cancer is treated, and to have CLASSY recognize this transformative potential.”
For more information about Cancer Research Institute, visit www.cancerresearch.org. To learn about the Annual CLASSY Awards, go to www.classyawards.org.
About the Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is the world’s only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 26 members of the National Academy of Sciences, CRI has invested $263 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to www.cancerresearch.org